Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129:299–306.
Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. J Struct Biol. 2000;130:280–9.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.
Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772–9.
Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med. 2016;54:1073–83.
Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, et al. Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1345–52.
Dwulet FE, O’Connor TP, Benson MD. Polymorphism in a kappa I primary (AL) amyloid protein (BAN). Mol Immunol. 1986;23:73–8.
Toft KG, Sletten K, Husby G. The amino-acid sequence of the variable region of a carbohydrate-containing amyloid fibril protein EPS (immunoglobulin light chain, type lambda). Biol Chem Hoppe Seyler. 1985;366:617–25.
Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid. 2000;7:200–11.
Dasari S, Theis JD, Vrana JA, Meureta OM, Quint PS, Muppa P, et al. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res. 2015;14:1957–67.
Connors LH, Jiang Y, Budnik M, Theberge R, Prokaeva T, Bodi KL, et al. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry. 2007;46:14259–71.
Sletten KWP, Husby G. Structural studies of the variable region of immunoglobulin light chain type amyloid fibril proteins. In: Glenner GGOE, Bendit EP, Calkins E, Cohen AS, Zucker-Franklin D, (ed). Amyloidosis. New York: Plennum Press; 1986. p. 463–75.
Sox HC Jr., Hood L. Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains. Proc Natl Acad Sci USA. 1970;66:975–82.
Ohkura T, Isobe T, Yamashita K, Kobata A. Structures of the carbohydrate moieties of two monoclonal human lambda-type immunoglobulin light chains. Biochemistry. 1985;24:503–8.
Youings A, Chang SC, Dwek RA, Scragg IG. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J. 1996;314(Pt 2):621–30.
We thank MeLea Hetrick and Mindy Kohlhagen for their help during experiments. This research was supported by Mayo Clinic, Rochester, MN, USA. This work was in part supported by the Predolin Foundation, the JABBS Foundation, a generous donation in the memory of Joey Bartzis, and by NIH grant CA125614.
SK performed the experiments and drafted the manuscript. SK, AD, DLM, and SD designed, analyzed, interpreted the data, and edited the manuscript. BM performed the LC-MS experiments. PM had performed the experiments on the 154 patients from a prior report. TK and SD had performed the analyses of tissue amyloid as per a prior publication. Other authors contributed intellectual content and review of this manuscript.
Conflict of interest
DLM and SD have financial interest in the MASS-FIX technology used in this study. All other authors declare that they have no conflict of interest.
About this article
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms
American Journal of Hematology (2018)